Pharming (PHAR) EBITDA Margin (2020 - 2025)
Historic EBITDA Margin for Pharming (PHAR) over the last 6 years, with Q3 2025 value amounting to 125.69%.
- Pharming's EBITDA Margin rose 1202000.0% to 125.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.04%, marking a year-over-year increase of 138900.0%. This contributed to the annual value of 2.9% for FY2024, which is 7000.0% down from last year.
- Per Pharming's latest filing, its EBITDA Margin stood at 125.69% for Q3 2025, which was up 1202000.0% from 2.21% recorded in Q2 2025.
- Pharming's EBITDA Margin's 5-year high stood at 484.88% during Q1 2022, with a 5-year trough of 29.35% in Q1 2024.
- Moreover, its 5-year median value for EBITDA Margin was 0.52% (2021), whereas its average is 32.59%.
- In the last 5 years, Pharming's EBITDA Margin crashed by -522000bps in 2021 and then skyrocketed by 4704600bps in 2022.
- Pharming's EBITDA Margin (Quarter) stood at 15.69% in 2021, then fell by -19bps to 18.68% in 2022, then soared by 64bps to 6.63% in 2023, then crashed by -40bps to 9.3% in 2024, then skyrocketed by 1451bps to 125.69% in 2025.
- Its EBITDA Margin stands at 125.69% for Q3 2025, versus 2.21% for Q2 2025 and 8.91% for Q1 2025.